Title: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing
Presenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals
 

Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals

Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals
 

Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al.
 

Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants
Authors: Thomas N. Kakuda, et al.

Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in
Healthy Chinese Adult Participants
Authors: Haiyan Li, et al.

Title: Short interfering RNA JNJ-3989 combination therapy in chronic 
hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Authors: Edward Gane, et al.
 

San Francisco, CA and online

Presentation Details: Title:

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) Authors: James Brugarolas, et al. Session: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers Abstract Number: 339 Poster Number: F9

James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”

Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation